<DOC>
	<DOC>NCT01636024</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and biomarkers in blood when the drug is administered inhaled to healthy subjects</brief_summary>
	<brief_title>To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594</brief_title>
	<detailed_description>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers</detailed_description>
	<criteria>Healthy male volunteers aged 1845 years inclusive with suitable veins for cannulation or repeated vein puncture Have a body mass index (BMI) between 18 and 30 kg/m2 and weight between 50 and 100 kg (inclusive) Be able to inhale from the Spira nebuliser used in the study Be willing to use a condom with spermicide to prevent pregnancy and drug exposure of a female partner History of any clinically significant disease or disorder Current smokers Any clinically relevant abnormal findings</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Phase 1,</keyword>
	<keyword>healthy volunteers,</keyword>
	<keyword>safety,</keyword>
	<keyword>tolerability,</keyword>
	<keyword>pharmacokinetics,</keyword>
	<keyword>pharmacodynamics,</keyword>
	<keyword>single ascending dose study,</keyword>
	<keyword>multiple</keyword>
</DOC>